

## AGN APPOINTS CEO DR LIZ DALLIMORE MANAGING DIRECTOR

**Perth, Australia; 4 APRIL 2022** - Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke, is pleased to provide an update on its Board composition as the Company moves heads into its Phase 1 clinical trial.

Today **Dr Liz Dallimore**, Argenica’s CEO has been appointed to the Board of the Company as Managing Director. Dr Dallimore has built significant shareholder value in AGN since listing in June 2021. Dr Dallimore has extensive experience in research and development, innovation, and management and is a welcome addition to the Board.

Argenica also welcomes Dr Meghan Thomas who commences with the company today as Head of Clinical Development. Dr Thomas will oversee Argenica’s clinical trial programmes, including the upcoming Phase 1 clinical trial of ARG-007.

Argenica Chairman, Geoff Pocock, commented “Liz’s appointment follows the positive outcomes achieved thus far as we progress to initiating our clinical trial. Liz’s deep understanding of neuroscience, combined with her extensive commercial acumen, has been invaluable to Argenica. We look forward to Liz’s ongoing leadership as the Company moves into the clinic, which is an incredibly exciting time for the Company. We also welcome Meghan to Argenica and very much look forward to her expertise and contribution she will make.”

Argenica’s CEO and Managing Director, Dr Liz Dallimore, commented “I am delighted to join the Board of Argenica. As a Company and team we are extremely excited about the potential for ARG-007 in ischaemic stroke, and the other applications we are pursuing. We look forward to commencing the Phase 1 clinical trial shortly, and moving our lead candidate forward through clinical development. I am also delighted that Meghan has commenced with Argenica, and very much look forward to working with her to achieve our development goals.”

In accordance with ASX listing rule 3.16.4 the Company advises of the following material variation to the terms of engagement of Dr Liz Dallimore as a result of the appointment. Dr Liz Dallimore’s Base Salary excluding superannuation will increase to \$250,000 per annum from \$220,000 per annum.

*This announcement has been approved for release by the Board of Argenica*

For more information please contact: [info@argenica.com.au](mailto:info@argenica.com.au)

## **ABOUT ARGENICA**

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicity before commencing Phase 1 clinical trials in humans. The aim is for our therapeutic to be administered by first responders to protect brain tissue against damage during a stroke with further potential to enhance recovery once a stroke has taken place.